Document Detail

Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors.
Jump to Full Text
MedLine Citation:
PMID:  23338230     Owner:  NLM     Status:  Publisher    
PURPOSE: Previous studies have not defined the role of telemonitoring with educational tools in outpatients with advanced cancers. We tested the effectiveness of standardized education and telemonitoring for improving pain, distress, anxiety, depression, quality of life (QoL), and performance in outpatients with advanced cancers. METHODS: A total of 108 patients were randomly assigned to receive pain education alone (control arm) or pain education plus telemonitoring (experimental arm). Nursing specialists provided video-assisted educational material in both arms and daily telemonitoring for the first week in the experimental arm. Assessment was performed at baseline and 1 week and included evaluations of pain (Brief Pain Inventory, BPI), distress (Distress Thermometer, DT), anxiety, and depression (Hospital Anxiety and Depression Scale, HADS), QoL (QLQ-C30), and a Karnofsky score. RESULTS: Overall (n = 108), pain intensity was significantly improved at 1 week, including worst pain (7.3 to 5.7, P < 0.01) and average pain (4.6 to 3.8, P < 0.01). Additionally, anxiety (HADS score ≥ 11, 75 % to 56 %, P < 0.01), depression (HADS score ≥ 11, 73 % to 51 %, P < 0.01), QoL (fatigue and insomnia), and the Karnofsky score (32 to 66, P < 0.01) were also significantly improved at 1 week. However, the level of distress did not improve. The telemonitoring plus standardized education group showed more significant improvement in portion of pain >4 on VAS scale (35 % vs. 19 %, P = 0.02). CONCLUSIONS: Standardized pain education using nursing specialists is an efficient way to improve not only pain itself but also anxiety, depression, performance, and QoL. The addition of telemonitoring helps to improve pain management in the outpatient setting.
Han Sang Kim; Sang Joon Shin; Sang Cheol Kim; Surim An; Sun Young Rha; Joong Bae Ahn; Byoung Chul Cho; Hye Jin Choi; Joo Hyuk Sohn; Hyo Song Kim; Hyun Cheol Chung; Joo Hang Kim; Jae Kyung Roh; Soohyeon Lee
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-23
Journal Detail:
Title:  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer     Volume:  -     ISSN:  1433-7339     ISO Abbreviation:  Support Care Cancer     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9302957     Medline TA:  Support Care Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Support Care Cancer
Journal ID (iso-abbrev): Support Care Cancer
ISSN: 0941-4355
ISSN: 1433-7339
Publisher: Springer-Verlag, Berlin/Heidelberg
Article Information
Download PDF
© The Author(s) 2013
Received Day: 13 Month: 7 Year: 2012
Accepted Day: 9 Month: 1 Year: 2013
Electronic publication date: Day: 23 Month: 1 Year: 2013
pmc-release publication date: Day: 23 Month: 1 Year: 2013
Print publication date: Month: 6 Year: 2013
Volume: 21 Issue: 6
First Page: 1751 Last Page: 1759
PubMed Id: 23338230
ID: 3641298
Publisher Id: 1722
DOI: 10.1007/s00520-013-1722-x

Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
Han Sang KimAff1
Sang Joon ShinAff1
Sang Cheol KimAff2
Surim AnAff1
Sun Young RhaAff1
Joong Bae AhnAff1
Byoung Chul ChoAff1
Hye Jin ChoiAff1
Joo Hyuk SohnAff1
Hyo Song KimAff1
Hyun Cheol ChungAff1
Joo Hang KimAff1
Jae Kyung RohAff1
Soohyeon LeeAff1 Address: +82-2-22288127 +82-2-3933652
Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea
Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea


Pain is one of the most common symptoms in patients with advanced cancer, and more than one-third of patients with pain rate it as moderate or severe [1]. Despite the existence of well-documented guidelines for cancer pain [2-4], nearly 50 % of patients are undertreated [5]. Unrelieved pain is associated with significant functional impairment, increased anxiety and depression, reduced quality of life (QoL) and might induce suicidal attempts [6-9].

Several factors have been identified as the main obstacles to relieving cancer pain and can be categorized according to patient, professional, and system perspectives [4, 7, 10-14]. Patients may be reluctant to communicate with physicians about pain because they consider the pain to represent progression of cancer, they may fear addiction or side effects of medications, and they may desire to be good patients. Physicians and nurses are not familiar with the principles of pain management and have insufficient time.

Educational interventions including videos and booklets have been applied to patients in previous research studies in order to overcome barriers to controlling cancer-related pain [14-17, 18-20]. Oliver et al. reported single exposure of individualized pain education could improve pain control in cancer outpatients [15]. Miaskowski et al. (1, 2, 4, and 5 weeks) and Yates et al. (1 and 2 weeks) provided multiple education sessions to enable self-care in pain control [16, 17]. Syrjala et al. utilized video tools with print materials [18]. These self-administered educational tools composed of a booklet and video helped patients to improve their knowledge and to actively cope with pain management. Recently, telecare management has been shown to improve pain and depression in patients with cancer [21]. Kroenke et al. improved patient outcomes in pain and depression through multiple education sessions regarding both pain and depression management, combined with telemonitoring (1, 4, and 12 weeks). However, previous studies have not defined the role of telemonitoring with standardized educational tools in outpatients with advanced cancer. More than 80 % of the patients with advanced cancer suffer from pain [4, 7], and there is insufficient time in outpatient clinics and it is difficult to conduct short-term follow-up; therefore, telemonitoring with educational tools may be effective in palliative and outpatient settings. In this study, our purpose was to evaluate whether standardized educational tools with or without telemonitoring in outpatients with advanced tumors could improve pain levels, pain interference, anxiety, depression, distress, performance, and QoL.

Patients and methods

This study was a randomized controlled trial. Between October 2010 and July 2011, a total of 108 patients at Severance Hospital were randomly assigned to receive standardized pain education only or standardized pain education plus telemonitoring for 1 week (Fig. 1). All patients were referred from treating oncologists to a pain clinic. Outcomes were evaluated at baseline and 1 week later in outpatient clinic. This study was approved by the Institutional Review Board of Severance Hospital (4-2010-0400).


Outpatients between 20 and 80 years old who had been diagnosed with a stage IV advanced solid tumor and experienced at least a moderate level of cancer-related pain, defined as an average Visual Analog Scale (VAS) score ≥4 of 10 over the last 24 h, were eligible. All of the patients had a life expectancy of more than 1 month. Both opioid-naïve and opioid-tolerant patients were eligible. We excluded patients who had cognitive, visual, or hearing impairment and patients who received hospice care or consultation for pain management, as these could be confounding factors. All patients signed a written informed consent.


At the time of enrollment, patients completed a baseline demographic questionnaire and were randomly stratified to either receive standardized pain education only or standardized pain education plus telemonitoring using coin toss simulation. For blinding, physicians and a nurse practitioner (NP) were not informed of the randomization.

In both the control and experimental arms, standardized pain education included individualized education and advice using a video-aided presentation and a booklet coached by NP on the first visit. Video-aided presentation and a booklet were totally based on the World Health Organization (WHO) pain control guidelines and National Comprehensive Cancer Network (NCCN) guideline. An NP who specialized in pain management coached each patient and caregivers together for approximately 30 min and checked the following components: baseline questionnaire including performance, the role of analgesics and misconception about using opioids, the importance of pain assessment, the WHO pain control guidelines, and management of pain based on the NCCN guideline. The booklet was composed of common pain management misconceptions, including fear of addiction and being a bad patient; pain assessment tools including VAS score; spaces for writing a pain diary; and the algorithm flow sheet for pain control. For individualization to each patient, a NP examined baseline pain medication and the level of knowledge using simple questions. Education was provided based on patients' knowledge. An example of how to adjust the medication was essentially given. After education and question and answer sessions, the proper pain dosage was recommended to each patient. The algorithm to determine pain control options was based on NCCN guideline. If the patient was not tolerable in oral intake, transdermal patch was recommended. After education, no further education session was allowed in a pain clinic after the first visit and routine practice by medical oncologists was provided after the intervention.

In the experimental arm, telemonitoring regarding pain was performed by an NP everyday for 1 week. The NP phoned the patients and asked for their average VAS pain score and worst VAS pain score in the last 24 h, providing patients a chance to assess the severity of pain by themselves. The NP advised patients whether to increase or decrease medication based on the NCCN guidelines for pain management. The NP was trained in pain management and had no specific training for other psychosocial interventions. The NP conducting telemonitoring is not the same person who performed the standardized education at the baseline. Telemonitoring was provided to patients for 1 week from the first visit.

Outcome measures

At baseline and 1 week after the first visit, we collected information on pain, distress, anxiety and depression, QoL, and performance status using a questionnaire in the outpatient clinic. For pain, average pain at 2 months was also collected. Outcome measures were as follows:

  1. Pain

Wisconsin Brief Pain Inventory (BPI) is a widely used standardized questionnaire for evaluating multiple aspects of pain. It rates the severity of pain, including worst, least, and average pain in the last 24 h, on a 0–10 scale along with the degree of interference [22]. Higher scores represent greater severity of symptoms.

  1. Anxiety and depression

Hospital Anxiety and Depression Scale (HADS) is a well-validated assessment questionnaire for anxiety and depression in patients with medical illness [23]. It is composed of seven depression and seven anxiety questions, respectively. Each item is scored from 0 to 3, so that possible scores range from 0 to 21 for each section. A score of 11 or higher indicates a mood disorder.

  1. Distress

Distress Thermometer (DT) is a well-validated tool for evaluating distress from 0 (no distress) to 10 (extreme distress) [24]. The 40-item Problem List was reviewed with patients to identify their problems in five different categories: practical, family, emotional, spiritual/religious, and physical issues.

  1. QoL

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a well-defined instrument containing 30 items for cancer patients [25]. It measures global QoL, functioning, and disease-related symptoms. A higher score for QoL represents a higher QoL.

  1. Performance

The Karnofsky performance score is a standardized tool for evaluating functional impairment. It runs from 100 to 0, and 100 means normal without complaints and 0 means death. Generally, scores less than 40 represent an inability to care for oneself and a requirement for hospital care. Scores from 40 to 70 indicate patients are able to live at home and care for most personal needs. Patients scoring higher than 70 are able to carry on normal activity and to work. Karnofsky performance rating criteria was provided to each patient and performance score was measured by a patient's self-report.

Statistical analysis

The primary endpoint of the study was a significant reduction of 20 % in the average pain scale (more than 4) in the standardized education plus telemonitoring group (30 %) compared to the standardized education only group (50 %). Baseline demographic data between the standardized education only and the standardized education plus telemonitoring groups were compared using independent Student's t tests for continuous data and chi-squared test for categorical data. Changes from baseline to 1 week were assessed within each group using paired t tests for continuous data and generalized logit model using generalized estimating equation approach for categorical data. P values were two-sided with 0.05 set as the level of significance. All calculations used actual data and adjustments were not made for missing data. Data analysis was performed using SPSS software (version 18.0).

Patient characteristics

One hundred and eight patients with newly diagnosed stage IV advanced solid tumors and with at least a moderate level of cancer-related pain were randomized to either standardized education (n = 54) or standardized education plus telemonitoring (n = 54) (Fig. 1). The demographic characteristics of the patients are summarized in Table 1. The overall mean age was 59.8 and there was a higher proportion of men (67.6 %). The most common cancer was gastrointestinal cancer, including stomach and colon (n = 39, 36.1 %), followed by lung (n = 23, 21.3 %) and head and neck cancer (n = 17, 15.7 %). Most patients were prescribed opioid analgesics (95.4 %). There were no significant differences in any of the demographics between the two groups.

Characteristics of the pain, distress, depression, anxiety, QoL, and performance at baseline

Baseline characteristics for outcomes are shown Table 2. Average and worst pain were 4.7 and 7.3, respectively, on a 0–10 scale, which indicates a substantial severity of pain. Three-fourths of the patients had a mood disorder, such as anxiety or depression. More than 90 % of patients had a level of distress that was clinically significant (distress scale ≥ 4). The mean global QoL score was 41 ± 18 on a 0–100 scale, which is poorer than 56.3, which is the reference value for recurrent or metastatic patients [26]. The mean Karnofsky performance score was 32, which indicates a requirement for special care and assistance. There were no significant intergroup differences in any of the outcome parameters at baseline.

Changes in pain, distress, depression, anxiety, QoL, and performance at 1 week in all patients (n = 108)

All pain scales were improved at 1 week, including worst (7.3 to 5.7, P < 0.01) and average pain (4.6 to 3.8, P < 0.01) (Table 3). There was a significant reduction in the proportion of patients whose pain scale was ≥4 (44 % to 28 %, P = 0.01). Interventions not only improved pain but also resolved other clinical outcomes, including anxiety (HADS score ≥ 11, 75 % to 56 %, P < 0.01), depression (HADS score ≥ 11, 73 % to 51 %, P < 0.01), and Karnofsky performance (32 to 66, P < 0.01). On the EORTC CTC-Q30 questionnaire, functional scales, including emotional, cognitive, and social functions, were improved. Symptomatic scales involving fatigue (68 to 63, P < 0.01), pain (90 to 76, P < 0.01), and insomnia (83 to 74, P < 0.01) were also improved, but constipation was increased (53 to 72, P < 0.01). The level of distress scale was not significantly decreased (distress scale ≥ 4, 92 % to 87 %, P = 0.27) and the average number of problems did not change (21 of total 40 problems, P = 0.49). Improved patient outcomes did not differ according to primary cancer types (data not shown).

Effect of the addition of telemonitoring for 1 week in patients receiving standardized pain education

To test for an additional effect of telemonitoring for 1 week in patients with standardized pain education, telemonitoring was added to the experimental arm (n = 54). Outcomes between groups are shown in Table 4. The portion of the patients with an average pain intensity ≥4 was significantly reduced in the standardized education plus telemonitoring groups compared to the standardized education only group (35 % to 19 %, P = 0.02). The average (−1.2 vs. −1.9) and worst (−0.7 vs. −1.2) pain scales decreased more in the telemonitoring group, but this was not statistically significant. Meanwhile, with regards to improving pain management, the addition of telemonitoring for pain did not show further improvement of psychiatric and other outcomes involving anxiety, depression, distress, QoL, and performance scores. The average pain scale at 1 week was maintained at 2 months in the standardized education group (3.9 to 4.0) (Fig. 2). In the telemonitoring group, the improved average pain scale at 1 week returned to the level of the standardized education group (3.6 to 4.1).


This study evaluated the effect of standardized pain education using a video and a booklet and compared the additional benefit of telemonitoring for pain in outpatients with advanced cancer. Outcomes included measurements not only of pain itself but also anxiety, depression, distress, QoL, and performance because we hypothesized pain improvement influences psychosocial aspects of patients with advanced cancer. After 1 week of education, outcomes including pain, anxiety, depression, QoL, and performance improved. The addition of telemonitoring to standardized pain education helped to improve pain management.

Patients with advanced cancer are frail and have a short life expectancy. Interventions for pain in this group are especially necessary as pain control would be the best of practice increasing QoL in the absence of active treatment options. We investigated this unmet need in terminal cancer patients in the outpatient setting. Above all, simplicity should be considered in this setting. Educational interventions have improved cancer pain in previous studies [14-17], and educational interventions involving both a video and booklet have been shown to be more effective in pain management than either alone [18, 19]. Recently, telecare for pain and depression by Kroenke et al. was shown to improve both outcomes in cancer patients compared to usual care for pain control [21]. In other words, more care and education naturally improve patient outcomes. However, considering practical issues, especially in the outpatient setting with advanced cancer patients, we needed to develop simple educational materials that are easily applicable to frail patients. Distinct from the study performed by Kroenke et al. [21], this study was focused on patients with terminal stage and provided the role of telemonitoring in pain management only. We also examined the effect of pain improvement on secondary outcomes (anxiety, depression, distress, QoL, and performance).

Patients with stage IV cancer showed considerable pain severity that impaired function (average pain of 4.7 in Table 2), which was comparable to a previous report [27]. Most patients had accompanying anxiety (75 %), depression (73 %), distress (92 %), and poor QoL and performance necessitating special care by caregivers. Interestingly, intervention for pain improved these physical and psychosocial outcomes in 1 week (Table 3). It is accepted that educational intervention improves knowledge of pain and analgesia and reduces patient barriers to using opioid medication and expressing pain intensity [14]. Several cross-sectional studies have shown that patients with pain have more frequent anxiety and depression and lower levels of performance and QoL than patients without pain [28-30]. However, it is controversial whether pain has a causal relationship with other factors, including anxiety, depression, and QoL. As intervention in this study was confined to pain only, our results may provide evidence that pain improvement induces betterment of physical and psychosocial factors with the exception of distress (Table 3). Distress is defined as a multifactorial unpleasant emotion combining psychological, social, and spiritual factors [24], and it is presumed that pain control alone is not sufficient for general distress improvement. As the impact of pain control on other physical or psychosocial factors might depend on the disease setting, the type of intervention, and the type of questionnaire, further studies are needed for each specific condition.

An effective schedule of educational intervention to improve cancer pain may depend on demographic (e.g., age), clinical (e.g., cancer type and stage), psychosocial (e.g., depression), and interindividual variability [31]. Our study showed improvement in a relatively short period of 1 week. Several explanations are possible. First, the patients' pain intensity was relatively high and generally, pain affects patients more significantly as it becomes more severe [27]. Second, the intervention could have a great impact on palliative patients for whom active treatment is not possible. The intervention might make patients perceive that they are receiving care and have a positive effect on outcomes. Third, allowing caregivers to receive standardized education may help improve outcomes. Because patients usually need a caregiver's assistance, most of the intervention was performed with patients and their caregiver. Though one 30-min session succeeded in improving outcomes, the effect of education diminished after 2 months (Fig. 2), and this implies multiple exposures might be necessary for palliative patients. Multiple exposures could be substituted for periodic telemonitoring. A subsequent trial is needed to identify the optimal schedule and period of telemonitoring in patients with advanced cancer.

The additional effect of telemonitoring was helpful for improving primary pain management but not secondary outcomes, such as distress, depression, anxiety, or QoL. Given that the standardized pain educational program alone improved pain and secondary outcomes, the additional yield of telemonitoring seemed to be small. However, daily telemonitoring for about 10 min is a simple way to monitor patients that does not require frequent visits to the clinic. Telemonitoring for pain and other psychosocial factors like depression also potentiate patient care [21].

There were two limitations in this study. First, the addition of telemonitoring improved the portion of average pain ≥4 but did not show significant improvement of other pain outcomes such as worst pain, average pain, and interference. One potential reason is 1 week might be short enough to show obvious differences. Opioid titration demands time to be fully adjusted. As optimal average pain score is less than 3 (mild pain), average pain of 3.6 in telemonitoring group after 1 week could be decreased to <3 if the telemonitoring is continued. Another reason could be owing to advanced disease setting. As pain in stage IV cancers is often severe, a short-term effect would be minimal between two groups. Long-term follow-up strategy should be addressed. Second, the initial Karnofsky score (<40, requires special care and assistance) could be lower than the actual value. In spite of initial low performance score, patients could undergo baseline screening with multiple variable assessments. This discrepancy is likely due to self-reported Karnofsky score. When patients were referred to a pain clinic for the first time, they suffered from uncontrolled pain. Unrelieved pain might affect their performance negatively.

In conclusion, standardized pain education using a nursing specialist is an efficient way to improve not only pain itself but also anxiety, depression, performance, and QoL in 1 week. The addition of telemonitoring helps to improve pain management, and telemonitoring is a simple intervention for outpatients with advanced tumors.


The paper was presented as an invited oral presentation and received young investigator award at the MASCC/ISOO 2012 International Symposium on Supportive Care in Cancer in New York City on June 28–30, 2012.

This work was financially supported by Janssen Pharmaceuticals. We used funds recruiting and training NPs and making educational materials.

Conflict of interest


1.. van den Beuken-van Everdingen MH,de Rijke JM,Kessels AG,Schouten HC,van Kleef M,Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 yearsAnn OncolYear: 20071891437144910.1093/annonc/mdm05617355955
2.. Ripamonti CI,Bandieri E,Roila F. Management of cancer pain: ESMO Clinical Practice GuidelinesAnn OncolYear: 201122Suppl 6vi69vi7710.1093/annonc/mdr39021908508
3.. National Comprehensive Cancer Network (NCCN) (2010) Clinical practice guidelines in oncology. Adult Cancer Pain
4.. Paice JA,Ferrell B. The management of cancer painCA Cancer J ClinYear: 201161315718210.3322/caac.2011221543825
5.. Deandrea S,Montanari M,Moja L,Apolone G. Prevalence of undertreatment in cancer pain. A review of published literatureAnn OncolYear: 200819121985199110.1093/annonc/mdn41918632721
6.. Zaza C,Baine N. Cancer pain and psychosocial factors: a critical review of the literatureJ Pain Symptom ManageYear: 200224552654210.1016/S0885-3924(02)00497-912547052
7.. Cohen MZ,Easley MK,Ellis C,Hughes B,Ownby K,Rashad BG,Rude M,Taft E,Westbrooks JB. Cancer pain management and the JCAHO's pain standards: an institutional challengeJ Pain Symptom ManageYear: 200325651952710.1016/S0885-3924(03)00068-X12782432
8.. Robson A,Scrutton F,Wilkinson L,MacLeod F. The risk of suicide in cancer patients: a review of the literaturePsycho-OncolYear: 201019121250125810.1002/pon.1717
9.. Anguiano L,Mayer DK,Piven ML,Rosenstein D. A literature review of suicide in cancer patientsCancer NursYear: 2012354E14E2610.1097/NCC.0b013e31822fc76c21946906
10.. Pargeon KL,Hailey BJ. Barriers to effective cancer pain management: a review of the literatureJ Pain Symptom ManageYear: 199918535836810.1016/S0885-3924(99)00097-410584460
11.. Potter VT,Wiseman CE,Dunn SM,Boyle FM. Patient barriers to optimal cancer pain controlPsychooncologyYear: 200312215316010.1002/pon.62712619147
12.. Elliott TE,Elliott BA. Physician attitudes and beliefs about use of morphine for cancer painJ Pain Symptom ManageYear: 19927314114810.1016/S0885-3924(06)80005-916967581
13.. Sun VC,Borneman T,Ferrell B,Piper B,Koczywas M,Choi K. Overcoming barriers to cancer pain management: an institutional change modelJ Pain Symptom ManageYear: 200734435936910.1016/j.jpainsymman.2006.12.01117616336
14.. Bennett MI,Bagnall AM,Jose Closs S. How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysisPainYear: 2009143319219910.1016/j.pain.2009.01.01619285376
15.. Oliver JW,Kravitz RL,Kaplan SH,Meyers FJ. Individualized patient education and coaching to improve pain control among cancer outpatientsJ Clin OncolYear: 20011982206221211304773
16.. Miaskowski C,Dodd M,West C,Schumacher K,Paul SM,Tripathy D,Koo P. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain managementJ Clin OncolYear: 20042291713172010.1200/JCO.2004.06.14015117994
17.. Yates P,Edwards H,Nash R,Aranda S,Purdie D,Najman J,Skerman H,Walsh A. A randomized controlled trial of a nurse-administered educational intervention for improving cancer pain management in ambulatory settingsPatient Educ CounsYear: 200453222723710.1016/S0738-3991(03)00165-415140463
18.. Syrjala KL,Abrams JR,Polissar NL,Hansberry J,Robison J,DuPen S,Stillman M,Fredrickson M,Rivkin S,Feldman E,Gralow J,Rieke JW,Raish RJ,Lee DJ,Cleeland CS,DuPen A. Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trialPainYear: 20081351–217518610.1016/j.pain.2007.10.02618093738
19.. Lovell MR,Forder PM,Stockler MR,Butow P,Briganti EM,Chye R,Goldstein D,Boyle FM. A randomized controlled trial of a standardized educational intervention for patients with cancer painJ Pain Symptom ManageYear: 2010401495910.1016/j.jpainsymman.2009.12.01320619212
20.. Lin CC,Chou PL,Wu SL,Chang YC,Lai YL. Long-term effectiveness of a patient and family pain education program on overcoming barriers to management of cancer painPainYear: 2006122327128110.1016/j.pain.2006.01.03916545909
21.. Kroenke K,Theobald D,Wu J,Norton K,Morrison G,Carpenter J,Tu W. Effect of telecare management on pain and depression in patients with cancer: a randomized trialJAMAYear: 2010304216317110.1001/jama.2010.94420628129
22.. Daut RL,Cleeland CS,Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseasesPainYear: 198317219721010.1016/0304-3959(83)90143-46646795
23.. Zigmond AS,Snaith RP. The hospital anxiety and depression scaleActa Psychiatr ScandYear: 198367636137010.1111/j.1600-0447.1983.tb09716.x6880820
24.. National Comprehensive Cancer Network (NCCN) (2010) Clinical practice guidelines in oncology. Distress Management
25.. Aaronson NK,Ahmedzai S,Bergman B,Bullinger M,Cull A,Duez NJ,Filiberti A,Flechtner H,Fleishman SB,de Haes JC,et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncologyJ Natl Cancer InstYear: 199385536537610.1093/jnci/85.5.3658433390
26.. Neil W Scott PMF, Neil K Aaronson, Andrew Bottomley, Alexander de Graeff, Mogens Groenvold, Chad Gundy, Michael Koller, Morten A Petersen, Mirjam AG Sprangers (2008) EORTC QLQ-C30 reference values
27.. Cleeland CS,Gonin R,Hatfield AK,Edmonson JH,Blum RH,Stewart JA,Pandya KJ. Pain and its treatment in outpatients with metastatic cancerNew Engl J MedYear: 1994330959259610.1056/NEJM1994030333009027508092
28.. Gerbershagen HJ,Ozgur E,Straub K,Dagtekin O,Gerbershagen K,Petzke F,Heidenreich A,Lehmann KA,Sabatowski R. Prevalence, severity, and chronicity of pain and general health-related quality of life in patients with localized prostate cancerEur J PainYear: 200812333935010.1016/j.ejpain.2007.07.00617855135
29.. Tavoli A,Montazeri A,Roshan R,Tavoli Z,Melyani M. Depression and quality of life in cancer patients with and without pain: the role of pain beliefsBMC CancerYear: 2008817710.1186/1471-2407-8-17718570676
30.. Lin CC,Lai YL,Ward SE. Effect of cancer pain on performance status, mood states, and level of hope among Taiwanese cancer patientsJ Pain Symptom ManageYear: 2003251293710.1016/S0885-3924(02)00542-012565186
31.. Miaskowski C. Patient education about cancer pain management: how much time is enough?PainYear: 20081351–21210.1016/j.pain.2007.12.00618222038


[Figure ID: Fig1]
Fig. 1 

Study overview

[Figure ID: Fig2]
Fig. 2 

Average pain scale at baseline, 1 week, and 2 months

[TableWrap ID: Tab1] Table 1 

Baseline characteristics of the 108 subjects

Characteristic Standardized education group (n = 54) Standardized education plus telemonitoring group (n = 54) Overall (n = 108) P value
Age (median, years) 59.5 61.7 59.8 0.73
Male, no. (%) 38 (70.4) 35 (64.8) 73 (67.6) 0.54
Female, no. (%) 16 (29.6) 19 (35.2) 35 (32.4)
Body mass index (BMI) 22.06 21.93 21.99 0.83
Type of cancer, no. (%)
  Breast 2 (3.7) 4 (7.4) 6 (5.6) 0.48
  Gastrointestinal tract 19 (35.2) 20 (37.0) 39 (36.1)
  Genitourinary tract 4 (7.4) 7 (13.0) 11 (10.2)
  Lung 15 (27.7) 8 (14.8) 23 (21.3)
  Head and neck 7 (13.0) 10 (18.5) 17 (15.7)
  Othera 7 (13.0) 5 (9.3) 12 (11.1)
Comorbidity, no. (%)
  Diabetes mellitus 3 (5.6) 7 (13.0) 10 (9.3) 0.76
  Hypertension 5 (9.3) 9 (16.7) 14 (13.0)
  Cerebrovascular  disease 0 0 0
  Heartb 2 (3.7) 2 (3.7) 4 (3.7)
  Lungc 2 (3.7) 1 (1.8) 3 (2.8)
  Chronic hepatitis 3 (5.6) 1 (1.8) 4 (3.7)
  Chronic renal failure 0 1 (1.8) 1 (0.9)
Pain medication, no. (%)
  Opioid analgesics 52 (96.3) 51 (94.4) 103 (95.4) 1.00
  Nonopioid  analgesics 2 (3.7) 3 (5.6) 5 (4.6)

aIncludes pancreas (n = 4), hepatome (n = 3), sarcoma (n = 2), primary peritoneal carcinomatosis (n = 1), giant cell tumor of the spine (n = 1), and primary unknown cancer (n = 1)

bIncludes patients with heart failure, angina, and arrhythmia

cIncludes patients with chronic obstructive lung disease and asthma

[TableWrap ID: Tab2] Table 2 

Baseline values for outcome measures (n = 108)

Outcome measures Standardized education group (n = 54) Standardized education plus telemonitoring group (n = 54) Overall (n = 108) P value
BPI Average pain 4.6 4.8 4.7 0.46
Worst pain 7.1 7.4 7.3 0.72
Interference 5.6 5.8 5.7 0.56
HADS Anxiety, n (%), ≥11 42 (78 %) 39 (72 %) 81 (75 %) 0.50
Depression, n (%), ≥11 41 (76 %) 38 (70 %) 79 (73 %) 0.52
DT Distress scale, n (%), ≥4 48 (88.9) 51 (94.4) 99 (91.7) 0.30
No. of problems—mean 21 21 21 0.42
Global quality of life, mean (SD) 41 (18.5) 42 (17.5) 41 (18.0) 0.83
Karnofsky performance, mean 33 31 32 0.24

BPI Brief Pain Inventory, HADS Hospital Anxiety and Depression Scale, DT Distress Thermometer, SD standard deviation

[TableWrap ID: Tab3] Table 3 

Overall course of clinical outcomes between baseline and 1 week

Clinical outcomes (n = 108) Baseline 1 week P value
BPI Worst pain 7.3 5.7 (−1.6) <0.01
Average pain 4.6 3.8 (−0.8) <0.01
Interference 5.7 5.2 (−0.5) <0.01
No. of pain scale (4–10) 48 (44 %) 30 (28 %) 0.01
HADS Anxiety, n (%), ≥11 81 (75 %) 60 (56 %) <0.01
Depression, n (%), ≥11 79 (73 %) 55 (51 %) <0.01
DT Distress scale ≥4, n (%) 99 (92 %) 94 (87 %) 0.27
No. of problems—mean 21 21 0.49
QoL Physical functioning, mean (SD) 52 (24) 56 (22) 0.10
Role functioning, mean (SD) 36 (21) 38 (19) 0.27
Emotional functioning, mean (SD) 45 (26) 56 (22) <0.01
Cognitive functioning, mean (SD) 47 (21) 55 (19) <0.01
Social functioning, mean (SD) 27 (17) 33 (17) <0.01
Global quality of life, mean (SD) 41 (18) 39 (15) 0.19
Karnofsky performance score—mean (SD) 32 (9.1) 66 (8.6) <0.01

BPI Brief Pain Inventory, HADS Hospital Anxiety and Depression Scale, DT Distress Thermometer, QoL quality of life, SD standard deviation

[TableWrap ID: Tab4] Table 4 

Clinical outcomes of the two groups

Clinical outcomes Standardized education group (n = 54) Standardized education plus telemonitoring group (n = 54) P value
BPI Worst pain Baseline 7.1 7.4 0.11
1 week 5.9 (−1.2) 5.5 (−1.9)
Average pain Baseline 4.6 4.8 0.24
1 week 3.9 (−0.7) 3.6 (−1.2)
Interference Baseline 5.6 5.8 0.44
1 week 5.2 (−0.4) 5.1 (−0.7)
No. of pain scale (4–10) Baseline 22 (41 %) 26 (48 %) 0.02
1 week 19 (35 %) 10 (19 %)
HADS Anxiety Baseline n (%), ≥11 42 (78 %) 39 (72 %) 0.34
1 week n (%), ≥11 29 (54 %) 31 (57 %)
Depression Baseline n (%), ≥11 41 (76 %) 38 (70 %) 0.64
1 week n (%), ≥11 28 (52 %) 27 (50 %)
DT Distress scale ≥4 Baseline n (%) 48 (89 %) 51 (94 %) 0.09
1 week n (%) 49 (91 %) 45 (83 %)
No. of problems—mean Baseline 21 21 0.35
1 week 21 20
QoL Physical functioning Baseline, mean (SD) 57 (22) 48 (25) 0.03
1 week, mean (SD) 55 (21) 56 (23)
Role functioning Baseline, mean (SD) 38 (20) 33 (23) 0.27
1 week, mean (SD) 38 (20) 38 (19)
Emotional functioning Baseline, mean (SD) 45 (25) 44 (27) 0.33
1 week, mean (SD) 54 (24) 58 (20)
Cognitive functioning Baseline, mean (SD) 49 (20) 45 (23) 0.13
1 week, mean (SD) 54 (17) 57 (20)
Social functioning Baseline, mean (SD) 27 (17) 28 (17) 0.69
1 week, mean (SD) 32 (18) 35 (17)
Global quality of life Baseline, mean (SD) 41 (19) 42 (18) 0.60
1 week, mean (SD) 38 (12) 40 (17)
Karnofsky performance score Baseline, mean (SD) 33 (9.4) 31 (8.7) 0.68
1 week, mean (SD) 65 (9.2) 66 (8.0)

BPI Brief Pain Inventory, HADS Hospital Anxiety and Depression Scale, DT Distress Thermometer, QoL quality of life, SD standard deviation

Article Categories:
  • Original Article

Keywords: Keywords Cancer, Pain, Care management, Telemonitoring, Quality of life.

Previous Document:  Predictive factors for overall quality of life in patients with advanced cancer.
Next Document:  Hair mass index obtained by cross-section trichometry: an objective and clinically useful parameter ...